AnserBio

About

Headcount over time

Offices

Q&A

What is AnserBio's primary focus?

AnserBio is a preclinical stage bio-oncology company focused on developing a novel approach to cancer treatment by delivering healthy p53 protein into tumor cells using proprietary cell-derived nanovesicles (exosomes).

When was AnserBio founded?

AnserBio was founded in January 2017.

What is the total amount of funding AnserBio has raised to date?

AnserBio has raised a total of $6,450,000 USD across all funding rounds.

Who are the co-founders of AnserBio?

The co-founders of AnserBio are Lana Volokh, PhD (Co-founder & CEO) and Alex Tendler, PhD (Co-founder & CTO).

What types of cancer is AnserBio's therapy being developed for?

AnserBio's therapy is being developed for various aggressive tumor types, including colon cancer, bladder cancer, ovarian cancer, and glioblastoma.

Team · 10

Lana Volokh, PhD

Founder · Co-founder & CEO, Director Scientist and executive

Alex Tendler, PhD

Founder · Co-founder & CTO, Director Scientist, engineer and entrepreneur

Yevgeny Tendler MD, PhD

Chief Scientist, Scientist, expert in cell biology

Roman Katz

CFO, Senior Manager

Alla Savchuk, BSc

Process technician

Yekaterina 'Katie' Chudnovsky

Board Member/Director

Xavier Grana, PhD

Consultant & Collaborator, Molecular Cell Biologist and Biochemist

Tomer Cooks, PhD

Consultant & Collaborator, Assistant Professor of Immunology and Microbiology

Gideon Shalev, PhD

Scientific Advisor, Expert in protein purification, drug development, and cancer research

Ksenia Tendler, PhD

Scientific Advisor, Expert in cell biology, stem cells, preclinical and translational cancer research

Sectors & technology

Highlights

Tags